A Systematic Review of the State of Economic Evaluation for Health Care in India

被引:65
作者
Prinja, Shankar [1 ]
Chauhan, Akashdeep Singh [1 ]
Angell, Blake [2 ]
Gupta, Indrani [3 ]
Jan, Stephen [2 ,4 ]
机构
[1] Post Grad Inst Med Educ & Res, Sch Publ Hlth, Sect 12, Chandigarh 160012, India
[2] George Inst Global Hlth, Camperdown, NSW 2050, Australia
[3] Univ Delhi Enclave, Inst Econ Growth, Hlth Policy Res Unit, Delhi 110007, India
[4] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
关键词
COST-EFFECTIVENESS ANALYSIS; HEPATITIS-B IMMUNIZATION; COMMON MENTAL-DISORDERS; ANTIRETROVIRAL THERAPY; VISCERAL LEISHMANIASIS; BENEFIT-ANALYSIS; CERVICAL-CANCER; HIV PREVENTION; ROTAVIRUS VACCINATION; JAPANESE ENCEPHALITIS;
D O I
10.1007/s40258-015-0201-6
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background and objective Economic evaluations are one of the important tools in policy making for rational allocation of resources. Given the very low public investment in the health sector in India, it is critical that resources are used wisely on interventions proven to yield best results. Hence, we undertook this study to assess the extent and quality of evidence for economic evaluation of health-care interventions and programmes in India. Methods A comprehensive search was conducted to search for published full economic evaluations pertaining to India and addressing a health-related intervention or programme. PubMed, Scopus, Embase, ScienceDirect, and York CRD database and websites of important research agencies were identified to search for economic evaluations published from January 1980 to the middle of November 2014. Two researchers independently assessed the quality of the studies based on Drummond and modelling checklist. Results Out of a total of 5013 articles enlisted after literature search, a total of 104 met the inclusion criteria for this systematic review. The majority of these papers were cost-effectiveness studies (64 %), led by a clinician or public-health professional (77 %), using decision analysis-based methods (59 %), published in an international journal (80 %) and addressing communicable diseases (58 %). In addition, 42 % were funded by an international funding agency or UN/bilateral aid agency, and 30 % focussed on pharmaceuticals. The average quality score of these full economic evaluations was 65.1 %. The major limitation was the inability to address uncertainties involved in modelling as only about one-third of the studies assessed modelling structural uncertainties (33 %), or ran sub-group analyses to account for heterogeneity (36.5 %) or analysed methodological uncertainty (32 %). Conclusion The existing literature on economic evaluations in India is inadequate to feed into sound policy making. There is an urgent need to generate awareness within the government of how economic evaluation can inform and benefit policy making, and at the same time build capacity of health-care professionals in understanding the economic principles of health-care delivery system.
引用
收藏
页码:595 / 613
页数:19
相关论文
共 134 条
[1]   Comparison of clinical and cost-effectiveness of psoralen plus ultraviolet A versus psoralen plus sunlight in the treatment of chronic plaque psoriasis in a developing economy [J].
Aggarwal, Komal ;
Khandpur, Sujay ;
Khanna, Neena ;
Sharma, Vinod K. ;
Pandav, Chandrakant S. .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2013, 52 (04) :478-485
[2]   Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model [J].
Aggarwal, R ;
Ghoshal, UC ;
Naik, SR .
JOURNAL OF HEPATOLOGY, 2003, 38 (02) :215-222
[3]  
Aggarwal R, 2002, NATL MED J INDIA, V15, P320
[4]   Economic implications of three strategies for the control of taeniasis [J].
Alexander, Anu ;
John, K. R. ;
Jayaraman, T. ;
Oommen, Anna ;
Raghava, M. Venkata ;
Dorny, Pierre ;
Rajshekhar, Vedantam .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2011, 16 (11) :1410-1416
[5]  
[Anonymous], APPR STAT PROGR IMPL
[6]  
[Anonymous], LIST ESSENTIAL DRUGS
[7]  
[Anonymous], APPR STAT PROGR IMPL
[8]  
[Anonymous], ONT GUID EC AN PHARM
[9]  
[Anonymous], VALUE HLTH S3S
[10]  
[Anonymous], 2014, BMC RES NOTES, DOI DOI 10.1186/1756-0500-7-177